A Phase 2 Study of Pamiparib (BGB-290) Plus Temozolomide for Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)
Latest Information Update: 19 May 2023
At a glance
- Drugs Pamiparib (Primary) ; Temozolomide (Primary)
- Indications Leiomyoma; Renal cell carcinoma
- Focus Therapeutic Use
- 15 May 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 15 Oct 2021 Status changed from not yet recruiting to recruiting.
- 07 Jul 2021 Planned initiation date changed from 1 Jun 2021 to 30 Dec 2021.